Voronoi, Inc.

Clinical trials sponsored by Voronoi, Inc., explained in plain language.

Voronoi, Inc. 310210 KOSDAQ

A clinical-stage biopharmaceutical company developing kinase inhibitors for cancer and inflammatory diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Will your breakfast ruin this cancer pill? new trial investigates Results expected Sep 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 2 Completed 1

Healthy volunteers help test how food and acid pills affect new drug absorption

Knowledge-focused Completed

This study looked at how taking VRN110755 with food or with a common stomach-acid drug (rabeprazole) changes the amount of drug in the blood. Twenty-five healthy adults took the drug under different conditions. The goal was to learn the best way to take the medicine in future stu…

Phase 1 • Sponsor: Voronoi, Inc • Aim: Knowledge-focused

Last updated Jun 27, 2026 12:30 UTC

Voronoi, Inc.

Upcoming readouts

Healthy volunteers help test how food and acid pills affect new drug absorption